Key result
Novel mechanism-based therapeutic strategies, including recombinant mutated human angiopoietin-like 4, sialylation-based therapeutics, Bis-T-23, and SuPAR depletion, show promise for treating chronic kidney disease.
Population
Patients and preclinical models with chronic kidney disease due to glomerular disorders
Design
Review
Authors
Loading...
These targeted glomerular therapies remain investigational; leaves open efficacy and safety in CKD pending rigorous trials.
Targeted therapies based on glomerular disease mechanisms, such as Angptl4 modulation and SuPAR depletion, offer promising future alternatives to current repurposed drugs for CKD.
Avila et al. (2016) conducted a review in Chronic kidney disease due to glomerular disorders. Novel therapeutic approaches (Angptl4, sialic acid precursors, Bis-T-23, SuPAR depletion) was evaluated. Novel mechanism-based therapeutic strategies, including recombinant mutated human angiopoietin-like 4, sialylation-based therapeutics, Bis-T-23, and SuPAR depletion, show promise for treating chronic kidney disease.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: